PMC9894891_01
Contrast-enhanced Magnetic Resonance Imaging (MRI) of the upper abdomen showed the patient's pancreatic carcinoma before (A) and after (B) the treatment of PD-1, HIFU and Gemcitabine. MRI showed the patient's liver metastasis before (C) and after (D) the treatment. CA199 (E) and carcinoembryonic antigen (CEA) (F) index of the patient.
fphar-14-1121122-g002.jpg
PMC9894891_01_fphar-14-1121122-g002.jpg
F2
Contrast-enhanced Magnetic Resonance Imaging (MRI) of the upper abdomen showed pancreatic head and uncinate process lesions and hepatic hemangioma in S2 and S3 segments (Figures 2A,C). The MRI imaging conferred significant tumor shrinkage (Figure 2B) and reduction of liver metastases on March 11(Figure 2D). Tumor markers significantly decreased (Figures 2E,F). And tumor markers elevated (Figures 2E,F).
Pelvic CT imaging showed the patient's immune ureteritis before (A) and after (B) the treatment of dexamethasone. The urine examination (C) of the patient.
fphar-14-1121122-g003.jpg
PMC9894891_01_fphar-14-1121122-g003.jpg
F3
August 14, pelvic CT (Figure 3A) showed that the wall of middle and lower sections of the left ureter was slightly thickened and dilated with fluid. Anti-infective treatments of ceftriaxone and levofloxacin were given for 2 weeks, and routine urine examinations showed no significant improvement. On August 22, routine urine examination markedly improved (Figure 3C). The patient's urinary symptoms significantly relieved and CT imaging of urinary tract (Figure 3B) also showed improvement.